ASX:AHZAdmedus Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Admedus Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsInsider TradesHeadlines Admedus Limited, a healthcare company, develops, commercializes, and distributes various medical technologies and devices. It manufactures, distributes, and sells proprietary ADAPT regenerative tissue products; and researches and develops regenerative medicine and immunotherapies. The company offers CardioCel, a bio-scaffold material to repair congenital heart deformities and other heart defects, as well as to reconstruct dysfunctional heart valves and valve leaflets; and CardioCel 3D that enables physicians access to an arch reconstruction solution with non-antigenic response and calcification resistance. It also provides VascuCel, a collagen scaffold used in cardiac repairs and reconstructions; ambIT infusion pumps for the delivery of medications and pain relief; arcomed infusion systems; and Eldor, a specialized fenestrated catheters for the infusion of local anesthetics into surgical sites for post-operative pain management. In addition, the company offers DOSI-FUSER, a portable elastomeric pump; and DOSI-PAIN, a wound catheter for postoperative continuous infusion. The company was formerly known as Allied Healthcare Group Limited and changed its name to Admedus Limited in November 2013. Admedus Limited is based in Toowong, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Admedus. Previous Next 2.5 Community Rank Outperform VotesAdmedus has received 1 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAdmedus has received 1 “underperform” votes. (Add your “underperform” vote.)Community SentimentAdmedus has received 50.00% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Admedus and other stocks. Vote “Outperform” if you believe AHZ will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AHZ will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAdmedus does not currently pay a dividend.Dividend GrowthAdmedus does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Admedus insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.50 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolASX:AHZ Previous Symbol CUSIPN/A CIKN/A Webwww.admedus.com Phone61 7 3152 3200Debt Debt-to-Equity Ratio16.85 Current Ratio2.82 Quick Ratio2.57Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$17.08 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueA$2.63 per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable Receive AHZ News and Ratings via Email Sign-up to receive the latest news and ratings for AHZ and its competitors with MarketBeat's FREE daily newsletter. Admedus (ASX:AHZ) Frequently Asked Questions Has Admedus been receiving favorable news coverage? Media stories about AHZ stock have been trending very negative recently, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Admedus earned a coverage optimism score of -3.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutAdmedus. Who are some of Admedus' key competitors? Some companies that are related to Admedus include Abattis Bioceuticals (ATTBF), ABcann Global (ABCN), ABZENA/PAR VTG FPD 0.002 (ABZA), Almirall (LBTSF), Amarantus Bioscience (AMBS), Antibe Therapeutics (VBIZF), Apotheca Biosciences (CBDC), Arno Therapeutics (ARNI), Axim Biotechnologies (AXIM), Baudax Bio (BXRXV), BerGenBio ASA (BRRGF), Biocure Technology (CURE), Canada House Wellness Group (CHV), Cannabics Pharmaceuticals (CNBX) and CannaRoyalty (ORHOF). View all competitors. Who are Admedus' key executives? Admedus' management team includes the following people: Mr. Wayne G. Paterson, CEO, Pres, MD & Exec. Director (Age 53)Mr. Matthew McDonnell, Chief Financial OfficerMr. David St. Denis, Chief Operating OfficerMs. Martha Engel, Gen. CounselDr. Kiran Bhirangi, Chief Medical Officer What is Admedus' stock symbol? Admedus trades on the ASX under the ticker symbol "AHZ." How big of a company is Admedus? Admedus has a market capitalization of $0.00 and generates $17.08 million in revenue each year. What is Admedus' official website? The official website for Admedus is www.admedus.com. How can I contact Admedus? The company can be reached via phone at 61 7 3152 3200. This page was last updated on 6/4/2020 by MarketBeat.com Staff
